MARTINSRIED and MUNICH, Germany, March 21 /PRNewswire/ -- MorphoSys AG (Neuer Markt: MOR), Munich/Germany today announced the achievement of the second milestone in their collaboration with Roche on HuCAL®-derived medications for the treatment of Alzheimer's Disease. MorphoSys delivered a series of HuCAL®-antibodies targeting the unspecified Roche antigen, which was shown by Roche researchers to bind selectively to the target in human Alzheimer brain tissue sections. This achievement triggers an undisclosed milestone payment from Roche to MorphoSys.
``We are extremely pleased with the rapid progress, which has exceeded our initial expectations,'' said Dr. John Kemp, Head of Preclinical CNS Research at Roche Basel.
``We made great progress by generating not one but a series of HuCAL-antibodies,'' commented Dr. Thomas von Rueden, Chief Scientific Officer, MorphoSys AG. ``We are very much looking forward to further positive results in this collaboration.''
Under the agreement, which was made public September 11, 2000, MorphoSys' HuCAL®-Fab library is being used to generate and to optimise antibodies to the Roche biological target. Roche will be responsible for the clinical development, regulatory approval, and worldwide marketing of any resulting products... |
